MP19-04 NATIONAL TREATMENT UTILIZATION PATTERNS FOR PATIENTS WITH METASTATIC CASTRATE SENSITIVE PROSTATE CANCER

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP19-04 NATIONAL TREATMENT UTILIZATION PATTERNS FOR PATIENTS WITH METASTATIC CASTRATE SENSITIVE PROSTATE CANCER Fahad Sheckley, Jennifer Nguyen, Teona Iarajuli, Michael Stifelman, and Nitin Yerram Fahad SheckleyFahad Sheckley More articles by this author , Jennifer NguyenJennifer Nguyen More articles by this author , Teona IarajuliTeona Iarajuli More articles by this author , Michael StifelmanMichael Stifelman More articles by this author , and Nitin YerramNitin Yerram More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003244.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The rapid evolution of treatments for metastatic castrate-sensitive prostate cancer (mCSPC) creates a challenge for providers to choose the best therapeutic strategy. Thus, most tend to rely on local practice patterns for guidance. We aim to report, by American Urological Association (AUA) sections, a retrospective analysis of treatment patterns and utilization in patients starting new therapy for mCSPC. METHODS: We conducted a retrospective analysis of fully adjudicated pharmacy and medical claims data from February 2015-2022, which included HIPAA-compliant information on diagnostic codes, tests, treatments, and procedures covering about 18 million U.S. cancer patients. Inclusion criteria for our study were males ≥18 years of age with at least one ICD 9/10 for prostate cancer and claim for treatment. Finally, a cohort identification process was performed to select for patients newly diagnosed with mCSPC. RESULTS: In total, 113,127 patients met our inclusion criteria and were analyzed. Results, summarized in Figure 1 (A&B), demonstrate trends in treatment for mCSPC for three select years. In 2015, LHRH-monotherapy was the most used treatment nationally at 56%, followed by first-generation anti-androgen (1st Gen AA; bicalutamide, etc) therapy at 33%. A reduction in usage of 1st Gen AA was noted (33% in 2015, 19% in 2018, 12% in 2021) with the introduction of novel hormone therapy (NHT; i.e. abiraterone, apalutamide, etc) in 2018. NHT usage rose from 27% in 2018 to 38% in 2021, with a concurrent drop in chemotherapy administration (12% in 2018, 9% in 2021). The AUA New England section reported the highest use of NHT in 2021 with 46%, while the North Central section reported the lowest at 36%. Urologists prescribed NHT to 9% of their patients with mCSPC in 2018 and 21% in 2021. CONCLUSIONS: As LHRH-monotherapy, first-generation anti-androgen and chemotherapy usage decline, NHT utilization has been rising, with more urologists prescribing novel treatments for mCSPC. As the trend continues, urologists may benefit from developing an internal workflow to prescribe NHT and monitor patients with mCSPC. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e265 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Fahad Sheckley More articles by this author Jennifer Nguyen More articles by this author Teona Iarajuli More articles by this author Michael Stifelman More articles by this author Nitin Yerram More articles by this author Expand All Advertisement PDF downloadLoading ...